ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Merger or Acquisition (January 2014)

24 slides from ThermoGenesis's merger presentation, Jan 29, 2014

  1. Slide 1: Critical Limb Ischemia Phase 1b Results

    Exhibit 99.1 % thermogenesis’ Filed by: ThermoGenesis Corp. Pursuant to Rule 425 under the Securities Act of 1933 ‘Subject Company: ThermoGenesis Corp. Commission File No: 000-16375 Critical Limb Ischemia Phase 1b Results Jan 2014 Clinical Trials.gov Notifier. NCT01472289 Safety and Efficacy of Auto

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation, including any comments made during or following the presentation, may contain forward- looking statements that are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. These statements may relate to, but are not

  3. Slide 3: Trial Collaborators

    Trial Collaborators Cell Processing Technology % | thermogenesis? — mses" Clinical Care e . Fortis Healthcare Ss [NSE: FORTIS] CLIRST - Clinical Trial Results ote = lotipotentRX*

  4. Slide 4: TotipotentRX Overview

    TotipotentRX Overview Private California-based cellular therapy research and development organization (www.totipotentrx.com), developing rapid bedside autologous cellular therapies for cardiovascular and orthopedic indications. Capabilities * Therapeutic Development (Cellular Products) + R&D, CRO, B

  5. Slide 5: CLI Overview

    CLI Overview Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It results in severe pain in the feet or toes, even while resting. Complications of poor circulation can induce sores and wounds that don't heal in the legs and

  6. Slide 6: CLI Statistics - Worldwide

    CLI Statistics - Worldwide Critical Limb Ischemia 1 year prognosis Alive with 2 limbs Amputation Cardio Mortality Target Market Statistics Europe India Population with CLI (PAD) 4-2M" 3M2 3M (20M)? Annual Diagnosis (Amputations) 400K (200K)* 375K-750K® (850K)® ‘Worgren L. etal, Eur J. Vasc. Endovasc

  7. Slide 7: Proposed Mechanism of Action

    Proposed Mechanism of Action Bone marrow progenitor cell concentrate Cell Preparation Reduced Blood Flow Aisesicen Hypoxic tissue Neovascularization Hypoxic tissue Intramuscular Injection Resident Progenitor cells + Disruption of Basement Membrane + Sprouting Angiogenesis {nto Capillary-lke Tunnels

  8. Slide 8: CLIRST Technology Minute Procedure & Integrated Kit

    CLIRST Technology 60 Minute Procedure & Integrated Kit Surgwerks™ CLI Single OR = Patented Visit | fe Technologies eos Integrated Technology CLIRST - Clinical Trial Results Tm = (lotipotentRX”

  9. Slide 9: CLIRST Study Design

    CLIRST Study Design Investigational Product: Autologous Bone Marrow Mononuclear Cells (BM-MNC) Indication Studied: Non-Reconstructable Critical Limb Ischemia (CLI) Objective: ies the safety and efficacy of autologous BMMNCs in CLI Number of patients: 17 (22 were screened) Study Duration: Approximate

  10. Slide 10: Inclusion / Exclusion Criteria

    Inclusion / Exclusion Criteria Inclusion Criteria + Patients with chronic and Critical Limb Ischemia with Rutherford Category IV & V, and Fontaine IV + Patients failed basic conservative and standard revascularization treatment (surgical / endovascular) + Major amputation recommended patients due to

  11. Slide 11: Trial Results: Safety Data (AE/SAEs)

    Trial Results: Safety Data (AE/SAEs) All patients tolerated 40 sites of intramuscular doses of bone marrow progenitors cells - total dose of 8x10® + 3.65 + Minorto moderate pain/discomfort for 8 h post implant expected and was clinically managed ~ 7 AE/SAEs were observed (all unrelated to the treatm

  12. Slide 12: Trial Results: Major Amputation Rate & Limb Salvage

    Trial Results: Major Amputation Rate & Limb Salvage CLIRST Probability Of Survival 1.00 0.75 0.50 0.25 0.00 Kaplan Meier Plot For Major Amputation Free Survival 100 N12 80 2 9 20 as Hi Lin savage > f Bi Major amputation Patient Population (n=17) 0.0 25 50 75 100 125 15.0 Duration (Months) legend: —

  13. Slide 13: Trial Results: Total Amputation Free Survival

    Trial Results: Total Amputation Free Survival Kaplan Meier Plot For Total Amputation Free Survival Efficacy In 1.00 = Brief: * 70.6% AFS; Cl= L 95% 0.75 * 12 Gf 17 i, z Patients Limbs = Total) Salvaged J 050 i wt (Total) 9 Ss e@ * Surviving with a 2 = 0 = Bh Amputation healthy leg 3 £ ag Free Surviv

  14. Slide 14: Trial Results: Blood Flow & Oxygenation

    Trial Results: Blood Flow & Oxygenation Analytics In Transcutaneous Oxygen Ankle Brachial Index Brief: Pressure (TcPO3) (AB!) TePO2 Values (Left - bars) 412 (Masaki et al) Patients averaged 14.66 mm Hg + 6.92 on enrollment +14 patients improved to 35.75 mm Hg + 17.04, p=0.0032 within 12 months ABI v

  15. Slide 15: Trial Results: Pain Scores

    Trial Results: Pain Scores Clinical In 32 Brief: Claudication (Left Axis) a *Claudication Pain (walking) reduced by 97% 25 *Baseline VAS score 7.8 + 0.97 on enrollment (on 2.0 asscale of 0-10) | +12 month VAS score 0.2 15 + 0.58, p=0.0005 Ff Rest Pain (Right Avis) . +Rest Pain reduced from moderate/

  16. Slide 16: Trial Results: Six Minute Walk Test

    Trial Results: Six Minute Walk Test Six Minute Walk Test 250 Clinical In Brief: No. of Subjects (Left Axis) f50 Number of Subjects Baseline 1 Month 3 Months 12 Months Follow-Up Period BB Able to Walk i Patient Withdrawal — Walking Distance TI Not Able toWalk Il Missing (Mean with 95% CI Improving pa

  17. Slide 17: Trial Results: Wound Closure

    Trial Results: Wound Closure R 10 Number of Subjects Clinical Examination of Ulcer, Gangrene, and Other Skin Changes (Y- Axis): No. of ball al = 7 Baseline 1 Month 3 Months 6 Months 12 Months Follow-Up Period D ker & Gangrene HE NoUlcer,Gangrene Ml NoUlker&NoGangrene Ml Missing i ulcer, No Gangrene

  18. Slide 18: Evidence of Vasculogenesis

    Evidence of Vasculogenesis Post-interyention CT Angiography Example of One Patient : Distal Thigh (P=0.01) Proximal Leg (P=0.03) Quantitative Results In Brief: + Analysis (proof) of collateral vessel improvementin treated leg + Vasculogenesis was documented originating from the distal thigh and prox

  19. Slide 19: Vasculogenesis: Verified Revascularization

    Vasculogenesis: Verified Revascularization CT-Angiograms — Qualitative and Quantitative analysis by an Independent Core Lab. Category Grade (No. of Collaterals) (Size of Collateral Vessels) Predntervention Post-intervention Prentewvention _Post-intervention Vessel mean (SD) mean (SD) pValue mean (SD

  20. Slide 20: Study Conclusions

    Study Conclusions The CLIRST achieved both the primary (safety) and secondary endpoints (efficacy) Safety + NoAE’ sor SAE’ srelated to the treatment Safety Endpoints * No change in retinal vascularization Achieved Efficacy * 82.4% major limb salvage, thus improving quality oflife Significant Clinica

  21. Slide 21: Next Steps

    Next Steps Submit an IDE-PMA application for Phase II/III by Q2 2014 + USA + India «+ UK Targeted Approvals: mt + USA FDA Ce. ) + India <a? | IRENE AC Se CLIRST - Clinical Trial Results Ta = lotiporentRX”

  22. Slide 22: Participant Recognition

    Participant Recognition Dr. Suhail Bukhari, MBBS, DNB ~ Head, Vascular Surgery, Fortis Escorts Heart Primary Investigator: Institute ach , 2 Dr. Venkatesh Ponemone, Ph.D., FACG, TotipotentRX Scientific Investigators: Dr Vijay Kumar, Ph.D., ThermoGenesis 2 Dr. Ashok Seth, MD, FRCP, FACC Sub Investiga

  23. Slide 23: Non-Solicitation

    Non-Solicitation This presentation and the information contained herein shall not constitute an offerto sell, buy or exchange or the solicitation of an offerto sell, buy or exchange any securities, nor shall there be any sale, purchase or exchange of securities in any jurisdiction in which such offe

  24. Slide 24: Thank You

    Thank You CLIRST - Clinical Trial Results 1274 To Stentroc

Thermogenesis — Merger or Acquisition (January 2014) on 6ix